gynecologic cancers: breast cancer

Studies

ID Name Stage Status
TABEA / GBG 43 Efficacy of taxane and bevacicumab ± capecitabine in firstline therapy metastatic
 active
Avastin 10/15 mg/kg Avastin 10/15 mg/kg metastatic
 active
Xeloda Xeloda metastatic
 active
ReTherapie Herceptin ReTherapie Herceptin metastatic
 active
HaBCS Hannover Breast Cancer Study metastatic
 active
HMBCS Hannover-Minsk Breast Cancer Study metastatic
 active
NIS-ODE-FAS-2009/1 ACT-FASTER various active
TARGIT-E TARGIT E(lderly) various active
MO22324 PHEREXA metastatic
 active
GBG51 MALE various active
MO22982 PrefHer Study various active
DETECT III Standard therapy +/- lapatinib in HER2-negative breast cancer metastatic
 active
  Netzwerkstudie: Genetische Prädiktoren des Therapieerfolges bei Brustkrebs various active
  BraWo NIS various active
  DAGMAR metastatic
 active
  Nabucco metastatic
 active
CFEM345DDE19 adjuvant
 closed
GEICAM/2006-11/GBG51 Women With Advanced or Metastatic Cancer With Indication of Hormonotherapy as First-line Treatment metastatic
 closed
TDM4450g T-DM1 vs. Trastuzumab / Docetaxel metastatic
 closed
CDR0000339738 Tamoxifen vs. anastrozol in DCIS DCIS
 closed
CZOL446GDE19 Letrozol ± Zoledronat (FEMZONE) neoadjuvant
 closed
TRAFO001 adjuvant
 closed
NIS-ODE-ARI-2008/1 Compliance and arthralgias in clinical therapy (CompACT) adjuvant
 closed
GBG53 dtEC->dtT vs. FEC->T (PANTHER) adjuvant
 closed
SUCCESS- B Gemcitabine-docetaxel vs.different biological biological treatment strategies adjuvant
 closed
SUCCESS-C FEC-doc-chemotherapy vs. doc-c-chemotherapy adjuvant
 closed
BCRA-Trail metastatic
 closed
SENTINA SENTINA (SENTInel NeoAdjuvant) neoadjuvant
 closed
RIBBON-3 metastatic 2nd line
 closed
BO20652 adjuvant
 closed
20060392 Observational study of skeletal complications (STARS) metastatic
 closed
Bondronat i.v. / ora metastatic
 closed
Herceptin 1 Herceptin 1 adjuvant
 closed
ISRCTN 34086741 TARGIT A various closed
Navelbine® oral metastatic
 closed